Expression of her-2 in carcinomas of the esophagus

American Journal of Surgical Pathology

Volumn 34, Issue 12, 2010, Pages 1868-1873

  Schoppmann, Sebastian F ^a   Jesch, Bettina ^b   Friedrich, Julia ^b   Wrba, Fritz ^b   Schultheis, Andrea ^c   Pluschnig, Ursula ^a   Maresch, Judith ^b   Zacherl, Johannes ^a   Hejna, Michael ^a   Birner, Peter ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Institute for Clinical Pathology   (Austria)

^c RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

distribution; esophageal cancer; her 2; prognosis; therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BARRETT ESOPHAGUS; ESOPHAGUS TUMOR; GENE AMPLIFICATION; GENE EXPRESSION; GENETICS; HUMAN; IN SITU HYBRIDIZATION; LOWER ESOPHAGUS SPHINCTER; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 78650359655     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181f8be17     Document Type: Article

References (33)

1. Adams AL, Eltoum I, Krontiras H, et al. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. Breast J. 2008;14:141-146.
2. Apple SK, Lowe AC, Rao PN, et al. Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer. Mod Pathol. 2009;22: 1151-1159.
3. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancer. Virchows Arch. 2005;446:489-496.
4. Bresalier RS. Barrett's Esophagus and esophageal adenocarcinoma. Annu Rev Med. 2009;60:221-231.
5. Brien TP, Odze RD, Sheehan CE, et al. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum Pathol. 2000;31:35-39.
6. Carneiro F, Sobrinho-Simoes M. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer. 2000;88:238-240.
7. Choueiri NE, Prather CM. Barrett's esophagus: a pre-cancerous condition approach to diagnosis and management. Mo Med. 2009; 106:339-342.
8. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:450-464.
9. D'Alfonso T, Liu YF, Monni S, et al. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed. Am J Surg Pathol. 2010;34:575-581.
10. Delektorskaya VV, Chemeris GY, Kononets PV, et al. Clinical significance of hyperexpression of epidermal growth factor receptors (EGFR and HER-2) in esophageal squamous cell carcinoma. Bull Exp Biol Med. 2009;148:241-245.
11. Dreilich M, Wanders A, Brattstrom D, et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus. 2006;19:224-231.
12. Geddert H, Zeriouh M, Wolter M, et al. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol. 2002;118:60-66.
13. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell Oncol. 2010;32:57-65.
14. Graham AJ, Shrive FM, Ghali WA, et al. Defining the optimal treatment of locally advanced esophageal cancer: a systematic review and decision analysis. Ann Thorac Surg. 2007;83:1257-1264.
15. Graham TA, McDonald SA. Genetic diversity during the development of Barrett's oesophagus-associated adenocarcinoma: how, when and why? Biochem Soc Trans. 2010;38:374-379.
16. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19: 1523-1529.
17. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52:797-805.
18. Kimchi ET, Posner MC, Park JO, et al. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. Cancer Res. 2005;65:3146-3154.
19. Langer R, Von Rahden BH, Nahrig J, et al. Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol. 2006;59:631-634.
20. Mimura K, Kono K, Hanawa M, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2005;92:1253-1260.
21. Ng T, Dipetrillo T, Purviance J, et al. Multimodality treatment of esophageal cancer: a review of the current status and future directions. Curr Oncol Rep. 2006;8:174-182.
22. Okines AF, Cunningham D. Trastuzumab in gastric cancer. Eur J Cancer. 2010;46:1949-1959.
23. Rauser S, Weis R, Braselmann H, et al. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin Cancer Res. 2007;13: 5115-5123.
24. Reichelt U, Duesedau P, Tsourlakis M, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocar-cinoma of the esophagus. Mod Pathol. 2007;20:120-129.
25. Riegman PH, Vissers KJ, Alers JC, et al. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res. 2001; 61:3164-3170.
26. Rossi E, Villanacci V, Bassotti G, et al. Her-2/neu in Barrett esophagus: a comparative study between histology, immunohisto-chemistry, and fluorescence in situ hybridization. Diagn Mol Pathol. 2006;15:125-130.
27. Sato-Kuwabara Y, Neves JI, Fregnani JH, et al. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer. 2009;9:6.
28. Sharma P. Clinical practice. Barrett's esophagus. N Engl J Med. 2009;361:2548-2556.
29. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457-1459.
30. Van Cutsem E, Y K, H C. Efficacy results from the ToGA trial: a phase III stduy of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). ASCO annual meeting. J Clin Oncol. 2009;LBA4509.
31. Walch A, Specht K, Bink K, et al. Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia- adenocarcinoma sequence of Barrett's esophagus. Lab Invest. 2001;81:791-801.
32. Yang H, Gu J, Wang KK, et al. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res. 2009;15:5744-5752.
33. Yonemura Y, Kojima N, Kawamura T, et al. Treatment results of adenocarcinoma of the gastroesophageal junction. Hepatogastroenterology. 2008;55:475-481.